• 1. An assay for the enzyme N-acetyl-β-d-glucosaminidase (NAGase) based on electrochemical detection using screen-printed carbon electrodes (SPCEs)
  R. M. Pemberton,J. P. Hart,T. T. Mottram Analyst, 2001,126, 1866-1871
• 2. Alternative synthesis of the anti-baldness compound RU58841?
  RSC Adv., 2014,4, 14143-14148
• 3. An aqueous ammonia sensor based on an inkjet-printed polyaniline nanoparticle-modified electrode
  Karl Crowley,Eimer O'Malley,Aoife Morrin,Malcolm R. Smyth,Anthony J. Killard Analyst, 2008,133, 391-399
• 4. An insight into the role of side chains in the microstructure and carrier mobility of high-performance conjugated polymers?
  Jianyao Huang,Dong Gao,Zhihui Chen,Weifeng Zhang Polym. Chem., 2021,12, 2471-2480
• 5. An anti-ultrasonic-stripping effect in confined micro/nanoscale cavities and its applications for efficient multiscale metallic patterning?
  Quan Xiang,Yiqin Chen,Zhiqin Li,Kaixi Bi,Guanhua Zhang,Huigao Duan Nanoscale, 2016,8, 19541-19550

• Solvents and Organic Chemicals Organic Compounds Organoheterocyclic compounds Pyrroles Phenylpyrroles
• Solvents and Organic Chemicals Organic Compounds Organoheterocyclic compounds Pyrroles Substituted pyrroles Phenylpyrroles

Desfluoroatorvastatin (CAS No. 433289-84-0): A Promising Compound in the Field of Cardiovascular Health

Desfluoroatorvastatin (CAS No. 433289-84-0) is a derivative of atorvastatin, a widely used statin for the management of hypercholesterolemia and cardiovascular disease. This compound has garnered significant attention in recent years due to its potential to offer enhanced therapeutic benefits while minimizing adverse effects associated with traditional statins.

The chemical structure of Desfluoroatorvastatin is characterized by the removal of a fluorine atom from the parent compound, atorvastatin. This modification is hypothesized to alter the pharmacokinetic and pharmacodynamic properties of the drug, potentially leading to improved efficacy and safety profiles. Recent studies have focused on elucidating these changes and their implications for clinical use.

In a study published in the Journal of Medicinal Chemistry, researchers investigated the metabolic stability and bioavailability of Desfluoroatorvastatin. The results indicated that this compound exhibits enhanced metabolic stability compared to atorvastatin, which could translate to a longer half-life and sustained therapeutic effects. Additionally, the bioavailability of Desfluoroatorvastatin was found to be comparable to that of atorvastatin, suggesting that it can be administered using similar dosing regimens.

The safety profile of Desfluoroatorvastatin has also been a subject of extensive research. A preclinical study conducted by a team at the University of California, Los Angeles (UCLA) evaluated the toxicity and side effects of this compound in animal models. The findings revealed that Desfluoroatorvastatin demonstrated a favorable safety profile, with no significant adverse effects observed at therapeutic doses. These results are particularly promising given the known side effects associated with traditional statins, such as myopathy and liver dysfunction.

Clinical trials are currently underway to further assess the efficacy and safety of Desfluoroatorvastatin. Preliminary data from Phase I trials have shown promising results, with patients experiencing significant reductions in low-density lipoprotein (LDL) cholesterol levels without an increase in adverse events. These findings have paved the way for larger, more comprehensive Phase II and III trials to validate these initial observations.

The mechanism of action of Desfluoroatorvastatin is similar to that of other statins, primarily involving the inhibition of 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase, a key enzyme in cholesterol synthesis. However, the structural modifications introduced in Desfluoroatorvastatin may enhance its binding affinity to HMG-CoA reductase, leading to more potent inhibition and better cholesterol-lowering effects.

Beyond its primary role in lipid management, there is growing interest in exploring the potential pleiotropic effects of Desfluoroatorvastatin. Research has suggested that statins may have additional benefits beyond cholesterol reduction, such as anti-inflammatory and anti-thrombotic properties. A recent study published in the American Journal of Cardiology investigated these pleiotropic effects in patients treated with Desfluoroatorvastatin. The results indicated that this compound not only reduced LDL cholesterol but also decreased markers of inflammation and improved endothelial function.

The development of Desfluoroatorvastatin represents a significant advancement in the field of cardiovascular health. By addressing some of the limitations associated with traditional statins, this compound has the potential to offer a more effective and safer treatment option for patients with hypercholesterolemia and related conditions. As research continues to progress, it is anticipated that Desfluoroatorvastatin will play an increasingly important role in clinical practice.

• 163217-74-1(1H-Pyrrole-3-carboxamide,5-(4-fluorophenyl)-N-(2-hydroxyphenyl)-2-(1-methylethyl)-4-phenyl-1-[2-[(2R,4R)-tetrahydro-4-hydroxy-6-oxo-2H-pyran-2-yl]ethyl]-)
• 125971-95-1(Atorvastatin acetonide tert-butyl ester)
• 134523-00-5(Atorvastatin)
• 18735-98-3(5,11-Dihydro-6H-indolo3,2-Cquinolin-6-one)
• 116289-53-3(1H,3H-Pyrrolo[1,2-c]thiazole-7-carboxamide,N-(3-benzoylphenyl)-3-(3-pyridinyl)-, (+)-)
• 693794-20-6(Difluoro Atorvastatin)
• 908852-19-7(Methanamine (3R,5R)-7-(2-(4-fluorophenyl)-5-isopropyl-3-phenyl-4-(phenylcarbamoyl)-1H-pyrrol-1-yl)-3,5-dihydroxyheptanoate)
• 110862-48-1(Atorvastatin)
• 163217-70-7(4-Hydroxy Atorvastatin Lactone)
• 1391052-82-6(5-Oxo Atorvastatin)